Mirati’s First KRAS Data Look At Least As Good As Amgen’s

Mirati Therapeutics Inc.’s first-in-human results for the KRAS G12C inhibitor MRTX849 appear to be at least as good as data disclosed to date for Amgen Inc.’s similarly targeted AMG 510 in lung and colorectal cancer patients with KRAS-expressing tumors that have G12C mutations, according to data presented on 28 October at an early stage research meeting hosted by the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer. 

Mirati’s results have been closely watched because MRTX849 is only the second drug against KRAS to show efficacy in patients whose tumors harbor this relatively common oncogene, which is...